Spain – Pharmaceutical products – Suministros de Nivolumab (DOE), Ipilimumab (DOE), Fedratinib (DOE), Luspatercept (DOE), Azacitidina (DOE) y Abatacept (DOE)
awardedOSAKIDETZA - Servicio Vasco de Salud - Organización Central · S5100023J
Value
€47m
Published
4 Nov 2026
Deadline
—
Type
award
33600000 · Medical equipment, pharmaceuticals & personal careES211
Description
L1_NIVOLUMAB (DOE)
Key facts
- Procedure
- neg-wo-call
- Contact
- contrata@osakidetza.eus
- Pre-award estimate
- €57m
- Regime
- publicSector
- Contract references
- 2026/01511252_00001
- Category
- supplies
Awarded suppliers
- BRISTOL-MYERS SQUIBB, S.A. · A28042463 · ES300, ES
Supplier location as published: Madrid, ES300, 28050, ES
Ground given for limiting competition
The buyer’s own stated reason for awarding without open competition, as published. Their assertion, not a finding.
technical
El presente procedimiento requiere de negociación para adjudicar la necesidad del contrato al licitador justificadamente elegido por el órgano de contratación. Ver Pliego de Cláusulas Administrativas
What a subscription adds to this notice
- The documents — every attachment, with its text extracted and searchable
- Qualification — the notice scored against your company profile
- Tracking and alerts — a pipeline for your bids, and the matching notices by email
- The API and MCP — the same record in your own tools and your AI assistant
Provenance
- Source
- ted-eu
- Notice id
- 765088-2026
- First seen
- 4 Nov 2026
- Last updated
- 4 Nov 2026
Licence EU reuse — Commission Decision 2011/833/EU ↗
Source: TED — Tenders Electronic Daily (ted.europa.eu), © European Union, reused under Commission Decision 2011/833/EU.
View at source ↗
GET /api/v1/tenders/625a4cf3-d5b5-45aa-bd54-c295d16df213The source notice is authoritative — verify deadlines and documents there before bidding.